Since established in 2019，Juncell Therapeutics stick to our mission of Rebuild cells, Rescue lives and the vision of Create miracles with tehnology. We pride ourselves in the values of Focus, Innovation, Inclusiveness, Sharing, attained several milestones during the company development.

2019

Our Company was established.

2020

We completed the construction of R&D laboratory and office in Shanghai.

We completed the pre-clinical study of TIL.

We completed our Series Pre-A Financing.

2021

The IIT was commenced for GC101.

We completed our Series A and Series A+ Financings.

2022

We completed the pre-clinical study for GC203.

We obtained NMPA IND approval for the clinical trial for GC101.

We commenced the Phase I clinical trial for GC101.

The IIT was commenced for GC203.

We completed our Series A++ Financing.

2023

We completed the safety evaluation of  the Phase I study for GC101.

2024

We obtained the NMPA IND approval to commence the Phase I clinical trial for GC203.

We commenced the Phase I clinical trial for GC203.

We commenced the Phase II clinical trial for GC101 for melanoma.

Our TIL cell manufacturing site in Shanghai commenced operation.

We commenced the Phase Ib clinical trial for GC101 for NSCLC.

We completed our Series B Financing.